The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension
Europe’s first dual orexin receptor antagonist – QUVIVIQTM (daridorexant) – granted approval
QUVIVIQTM (daridorexant) is now available in the US for adults
living with insomnia
PIVLAZTM (clazosentan) – Idorsia’s
first commercial product – now
available for patients in Japan
Results of the
2022 Annual General
Meeting of Shareholders
Daridorexant Phase 3
data published in
The Lancet Neurology
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia’s success depends on its people.
Idorsia's development compounds target a number of different diseases.
| 16 Nov 2022 | |
| 15 Nov 2022 | |
| 13 Nov 2022 |
| Event | When |
|
Full-Year 2022 Financial Results reporting* |
February 7, 2023
|
|
First Quarter 2023 Financial Results reporting* |
April 25, 2023
|
|
Annual General Meeting of Shareholders |
May 4, 2023 |
|
Half-Year 2023 Financial Results reporting* |
July 25, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
